| 000 | 05075cam a2200541Ii 4500 | ||
|---|---|---|---|
| 999 |
_c89663 _d89663 |
||
| 005 | 20250310101824.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 250310b ||||| |||| 00| 0 eng d | ||
| 020 |
_a9781119678281 _q(cloth) |
||
| 020 |
_a9781119678366 _q(electronic bk. : oBook) |
||
| 020 |
_a1119678366 _q(electronic bk. : oBook) |
||
| 020 |
_a9781119678373 _q(epub) |
||
| 020 |
_a1119678374 _q(epub) |
||
| 020 |
_a9781119678274 _q(adobe pdf) |
||
| 020 |
_a1119678277 _q(adobe pdf) |
||
| 024 | 7 |
_a10.1002/9781119678366 _2doi |
|
| 035 |
_a(OCoLC)1284917134 _z(OCoLC)1284919037 |
||
| 040 |
_aDLC _beng _erda _cDLC _dDG1 _dOCLCO _dOCLCF _dOCLCO |
||
| 041 | _aeng | ||
| 042 | _apcc | ||
| 050 | 0 | 0 | _aRM301.5 |
| 060 | 0 | 0 | _aQV 35 |
| 082 | 0 | 0 |
_a615.7 _223 |
| 130 | 0 | _aBiopharmaceutics (Batchelor) | |
| 245 | 1 | 0 |
_aBiopharmaceutics : _bfrom fundamentals to industrial practice / _cedited by Hannah Batchelor. |
| 250 | _aFirst edition. | ||
| 264 | 1 |
_aChichester, UK ; _aHoboken, NJ : _bJohn Wiley & Sons, _c2022. |
|
| 300 | _a1 online resource. | ||
| 336 |
_atext _btxt _2rdacontent. |
||
| 337 |
_acomputer _bc _2rdamedia. |
||
| 338 |
_aonline resource _bcr _2rdacarrier. |
||
| 490 | 1 | _aAdvances in pharmaceutical technology. | |
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | 0 | _aAn introduction to biopharmaceutics / Hannah Batchelor -- Basic pharmacokinetics / Hamid A. Merchant -- Introduction to biopharmaceutics measures / Hannah Batchelor and Pavel Gershkovich -- Solubility / Hannah Batchelor -- Permeability / Chris Roe and Vanessa Zann -- Dissolution / Hannah Batchelor and James Butler -- Biopharmaceutics to inform candidate drug selection and optimisation / Linette Ruston -- Biopharmaceutics tools for rational formulation design / Panagiota Zarmpi, Mark McAllister, James Butler, and Nikoletta Fotaki -- Biopharmaceutic classification system / Hannah Batchelor and Talia Flanagan -- Regulatory biopharmaceutics / Shanoo Budhdeo, Paul A. Dickinson, and Talia Flanagan -- Impact of anatomy and physiology / Francesca K. H. Gavins, Christine M. Madla, Sarah J. Trenfield, Laura E. McCoubrey, Abdul W. Basit, and Mark McAllister -- Integrating biopharmaceutics to predict oral absorption using PBPK modelling / Konstantinos Stamatopoulos -- Special populations / Christine M. Madla, Francesca K. H. Gavins, Sarah J. Trenfield, and Abdul W. Basit -- Inhalation biopharmaceutics / Precious Akhuemokhan, Magda Swedrowska and Ben Forbes -- Biopharmaceutics of injectable formulations / Wang Wang Lee and Claire M. Patterson -- Biopharmaceutics of topical and transdermal formulations / Hannah Batchelor -- Impact of the microbiome on oral biopharmaceutics / Laura E. McCoubrey, Hannah Batchelor, Abdul W. Basit, Simon Gaisford, and Mine Orlu. | |
| 520 |
_a"This book arose as a result of this mission where the members of the focus group recognised the need to provide training for those wanting to better understand biopharmaceutics and serves as a handbook to introduce the tools used within biopharmaceutics as applied to drug development. The first six chapters cover the basics of biopharmaceutics and provide the context that underpins the later chapters. Chapters 7 and 8 specifically deal with how biopharmaceutics is integrated into product development within the pharmaceutical industry. Chapters 9 and 10 provide information on the regulatory aspects of biopharmaceutics. Chapter 11 highlights the impact of physiology and anatomy and how this can affect the rate and extent of drug absorption. Physiologically based modelling is a valuable asset in the biopharmaceutics toolkit, and this is introduced in Chapter 12. Chapter 13 provides information on a more advanced topic, the application of biopharmaceutics to special populations. Although oral administration remains the mainstay of drug therapy, it is not the exclusive route of administration, Chapters 14-16 cover alternative routes of administration. A newly emerging topic that considers the impact of the microbiome on the rate and extent of drug absorption is included as the final chapter in this book"-- _cProvided by publisher. |
||
| 545 | 0 | _aAbout the Author Edited by Hannah Batchelor, Strathclyde Institute of Pharmacy and Biomedical Sciences. | |
| 650 | 0 |
_aBiopharmaceutics. _0http://id.loc.gov/authorities/subjects/sh85014252. |
|
| 650 | 0 |
_aDrugs _xDesign. _0http://id.loc.gov/authorities/subjects/sh88001157. |
|
| 650 | 1 | 2 |
_aBiopharmaceutics _xmethods. _0https://id.nlm.nih.gov/mesh/D001702Q000379. |
| 650 | 2 | 2 |
_aDrug Design. _0https://id.nlm.nih.gov/mesh/D015195. |
| 650 | 2 |
_aBiopharmaceutics. _0https://id.nlm.nih.gov/mesh/D001702. |
|
| 655 | 4 | _aElectronic books. | |
| 700 | 1 |
_aBatchelor, Hannah, _0http://id.loc.gov/authorities/names/n2021183332 _eeditor. |
|
| 830 | 0 |
_aAdvances in pharmaceutical technology. _0http://id.loc.gov/authorities/names/n2013182303. |
|
| 856 | 4 | 0 |
_uhttps://onlinelibrary.wiley.com/doi/book/10.1002/9781119678366 _yFull text available at Wiley Online Library Click here to view |
| 942 |
_2ddc _cER |
||